Not available
Quote | Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Last: | $41.87 |
---|---|
Change Percent: | -0.21% |
Open: | $42.7 |
Close: | $41.87 |
High: | $43.08 |
Low: | $41.76 |
Volume: | 802,954 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's c...
2024-05-02 20:28:09 ET Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Conference Call May 02, 2024, 17:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Ch...
Message Board Posts | Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Subject | By | Source | When |
---|---|---|---|
News; $RARE Ultragenyx Pharmaceutical Inc ($RARE) Q3 2020 | whytestocks | investorshub | 10/28/2020 11:15:29 AM |
Lets go !!! | Erz | investorshub | 06/02/2020 7:04:41 PM |
News: $RARE Ultragenyx Announces Sale of Future European | whytestocks | investorshub | 12/19/2019 2:00:42 AM |
News: $RARE Ultragenyx Expands Leadership Team and Promotes | whytestocks | investorshub | 06/17/2019 8:50:42 PM |
What does this Miss Primary end points mean | Scalp2Trade | investorshub | 10/26/2018 1:07:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the develo...
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's c...
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 ...